Publications by authors named "Reiko Isa"

Claim this Profile
C
Case Report: Immunophenotypically diverse immature patterns, including variable TdT expression, in aggressive B-cell lymphomas and leukemia with rearrangement.
Daishi Kato, Takahiro Fujino, Reiko Isa, Haruya Okamoto, Taku Tsukamoto

Front Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: a multicenter retrospective study.
Takahiro Fujino, Haruya Okamoto, Daichi Nishiyama, Hiroki Hayata, Nana Sasaki, Reiko Isa

Leuk Lymphoma· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Robust anti-myeloma effect of TAS0612, an RSK/AKT/S6K inhibitor, with venetoclax regardless of cytogenetic abnormalities.
Haruya Okamoto, Shinsuke Mizutani, Taku Tsukamoto, Yoko Katsuragawa-Taminishi, Yuka Kawaji-Kanayama, Reiko Isa

Leukemia· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic model for relapsed/refractory transplant-ineligible diffuse large B-cell lymphoma utilizing the lymphocyte-to-monocyte ratio.
Daisuke Ide, Takahiro Fujino, Tsutomu Kobayashi, Aya Egashira, Akihiro Miyashita, Reiko Isa

Int J Hematol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
miR-17-92 cluster-BTG2 axis regulates B-cell receptor signaling in mantle cell lymphoma.
Yuka Kawaji-Kanayama, Taku Tsukamoto, Masakazu Nakano, Yuichi Tokuda, Hiroaki Nagata, Reiko Isa

Cancer Sci· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative impact of immunoparesis in response to anti-SARS-CoV-2 mRNA vaccination of patients with multiple myeloma.
Akio Onishi, Yayoi Matsumura-Kimoto, Shinsuke Mizutani, Reiko Isa, Takahiro Fujino

Int J Hematol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triple targeting of RSK, AKT, and S6K as pivotal downstream effectors of PDPK1 by TAS0612 in B-cell lymphomas.
Yoko Katsuragawa-Taminishi, Shinsuke Mizutani, Yuka Kawaji-Kanayama, Akio Onishi, Haruya Okamoto, Reiko Isa

Cancer Sci· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumour-derived exosomes promote the induction of monocytic myeloid-derived suppressor cells from peripheral blood mononuclear cells by delivering miR-106a-5p and miR-146a-5p in multiple myeloma.
Kentaro Mizuhara, Yuji Shimura, Taku Tsukamoto, Akinori Kanai, Saeko Kuwahara-Ota, Reiko Isa

Br J Haematol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Watchful waiting is an acceptable treatment option for asymptomatic primary ocular adnexal mucosa-associated lymphoid tissue lymphoma: A retrospective study.
Kentaro Mizuhara, Tsutomu Kobayashi, Mitsushige Nakao, Ryoichi Takahashi, Hiroto Kaneko, Reiko Isa

Cancer Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Implication of the Effect of the Production of Neutralizing Antibodies Against SARS-Cov-2 for Chronic Immune Thrombocytopenia Flare-Up Associated with COVID-19 Infection: A Case Report and the Review of Literature.
Chika Maekura, Ayako Muramatsu, Hiroaki Nagata, Haruya Okamoto, Akio Onishi, Reiko Isa

Infect Drug Resist· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study.
Yuka Kawaji-Kanayama, Ayako Muramatsu, Nana Sasaki, Kazuho Shimura, Miki Kiyota, Reiko Isa

Int J Hematol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma.
Reiko Isa, Mano Horinaka, Taku Tsukamoto, Kentaro Mizuhara, Yuto Fujibayashi

Int J Mol Sci· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of Bone Marrow Biopsy and Flow Cytometric Analysis: The Prognostically Relevant Central Approach for Detecting Bone Marrow Invasion in Diffuse Large B-Cell Lymphoma.
Haruya Okamoto, Nobuhiko Uoshima, Ayako Muramatsu, Reiko Isa, Takahiro Fujino

Diagnostics (Basel)· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EWSR1 overexpression is a pro-oncogenic event in multiple myeloma.
Daichi Nishiyama, Yoshiaki Chinen, Reiko Isa, Yuto Fujibayashi, Saeko Kuwahara-Ota

Int J Hematol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma.
Saeko Kuwahara-Ota, Yuji Shimura, Christian Steinebach, Reiko Isa, Junko Yamaguchi

Br J Haematol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toward further simplification of elotuzumab therapy by subcutaneous administration.
Yuji Shimura, Taku Tsukamoto, Junko Yamaguchi, Saeko Kuwahara-Ota, Reiko Isa

Int J Hematol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aberrant BUB1 Overexpression Promotes Mitotic Segregation Errors and Chromosomal Instability in Multiple Myeloma.
Yuto Fujibayashi, Reiko Isa, Daichi Nishiyama, Natsumi Sakamoto-Inada, Norichika Kawasumi

Cancers (Basel)· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma.
Yayoi Matsumura-Kimoto, Taku Tsukamoto, Yuji Shimura, Yoshiaki Chinen, Kazuna Tanba, Reiko Isa

Cancer Med· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma.
Reiko Isa, Nobuhiko Uoshima, Ryoichi Takahashi, Sonoko Nakano-Akamatsu, Eri Kawata

Ann Hematol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia.
Junko Yamaguchi, Takahiro Fujino, Reiko Isa, Daichi Nishiyama, Saeko Kuwahara-Ota

Haematologica· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxic epidermal necrolysis in adult T cell leukemia/lymphoma treated with mogamulizumab.
Kazuna Tanba, Nobuhiko Uoshima, Hitoji Uchiyama, Eri Kawata, Reiko Isa

Ann Hematol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diffuse large B-cell lymphoma presenting with central pontine myelinolysis: a case report.
Eri Kawata, Reiko Isa, Junko Yamaguchi, Kazuna Tanba, Yasuhiko Tsutsumi

J Med Case Rep· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis